Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1979 1
1986 1
1988 2
1989 2
1991 2
1992 1
1993 1
1994 2
1995 2
1996 2
1997 1
1998 1
1999 4
2000 5
2001 1
2002 1
2003 4
2004 2
2005 4
2006 2
2007 7
2008 9
2009 6
2010 6
2011 3
2012 4
2013 1
2014 3
2015 4
2016 1
2017 5
2018 6
2019 5
2020 19
2021 13
2022 16
2023 28
2024 21
2025 14
2026 4

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

190 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for f hein
Search for F Aein instead (2 results)
Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial.
Pfisterer J, Shannon CM, Baumann K, Rau J, Harter P, Joly F, Sehouli J, Canzler U, Schmalfeldt B, Dean AP, Hein A, Zeimet AG, Hanker LC, Petit T, Marmé F, El-Balat A, Glasspool R, de Gregorio N, Mahner S, Meniawy TM, Park-Simon TW, Mouret-Reynier MA, Costan C, Meier W, Reinthaller A, Goh JC, L'Haridon T, Baron Hay S, Kommoss S, du Bois A, Kurtz JE; AGO-OVAR 2.21/ENGOT-ov 18 Investigators. Pfisterer J, et al. Lancet Oncol. 2020 May;21(5):699-709. doi: 10.1016/S1470-2045(20)30142-X. Epub 2020 Apr 16. Lancet Oncol. 2020. PMID: 32305099 Free article. Clinical Trial.
INTERPRETATION: Carboplatin-pegylated liposomal doxorubicin-bevacizumab is a new standard treatment option for platinum-eligible recurrent ovarian cancer. FUNDING: F Hoffmann-La Roche....
INTERPRETATION: Carboplatin-pegylated liposomal doxorubicin-bevacizumab is a new standard treatment option for platinum-eligible recurrent o …
Odontoblasts are cold sensory cells in teeth: Comment on: L. Bernal, P. Sotelo-Hitschfeld, C. Konig, V. Sinica, A. Wyatt, Z. Winter, A. Hein, F. Touska, S. Reinhardt, A. Tragl, R. Kusuda, P. Wartenberg, A. Sclaroff, J. D. Pfeifer, F. Ectors, A. Dahl, M. Freichel, V. Vlachova, S. Brauchi, C. Roza, U. Boehm, D. E. Clapham, J. K. Lennerz, K. Zimmermann, Odontoblast TRPC5 channels signal cold pain in teeth. Sci. Adv. 7, eabf5567 (2021).
Sotelo-Hitschfeld P, Bernal L, Zimmermann K. Sotelo-Hitschfeld P, et al. Temperature (Austin). 2021 Jul 28;10(1):9-12. doi: 10.1080/23328940.2021.1933365. eCollection 2023. Temperature (Austin). 2021. PMID: 37187828 Free PMC article. No abstract available.
Impact of baseline (18)F-flotufolastat PET bone tumor volume for prognosticating severe hematologic toxicity in patients with metastatic castration-resistant prostate Cancer receiving (177)Lu-PSMA-targeted radioligand therapy.
Karimzadeh A, Hansen K, Hein S, Haller B, Heck MM, Tauber R, D Alessandria C, Eiber M, Rauscher I. Karimzadeh A, et al. Eur J Nucl Med Mol Imaging. 2025 Oct;52(12):4434-4445. doi: 10.1007/s00259-025-07200-7. Epub 2025 May 19. Eur J Nucl Med Mol Imaging. 2025. PMID: 40383857 Free PMC article.
PURPOSE: This retrospective analysis evaluated the prognostic value of baseline (18)F-flotufolastat-PET bone tumor metrics for severe hematologic toxicity in metastatic castration-resistant prostate cancer (mCRPC) patients treated with [(177)Lu]Lu-PSMA-I&T. METHODS: Da …
PURPOSE: This retrospective analysis evaluated the prognostic value of baseline (18)F-flotufolastat-PET bone tumor metrics for severe …
εγ-Thalassemia, a New Hemoglobinopathy Category.
Oliveira JL, Thompson CH, Saravanaperumal SA, Koganti T, Jenkinson G, Hein MS, Kohorst MA, Hasadsri L, Nguyen PL, Matern D, Kipp BR, Klee EW, Wieben ED, Hoyer JD, Rangan A. Oliveira JL, et al. Clin Chem. 2023 Jul 5;69(7):711-717. doi: 10.1093/clinchem/hvad038. Clin Chem. 2023. PMID: 37086467
BACKGROUND: Large beta-globin gene cluster deletions (hereditary persistence of fetal hemoglobin [Hb] or beta-, deltabeta-, gammadeltabeta-, and gammadeltabeta-thalassemia), are associated with widely disparate phenotypes, including variable degrees of microcytic anemia and Hb …
BACKGROUND: Large beta-globin gene cluster deletions (hereditary persistence of fetal hemoglobin [Hb] or beta-, deltabeta-, gammadeltabeta-, …
Metrics reloaded: recommendations for image analysis validation.
Maier-Hein L, Reinke A, Godau P, Tizabi MD, Buettner F, Christodoulou E, Glocker B, Isensee F, Kleesiek J, Kozubek M, Reyes M, Riegler MA, Wiesenfarth M, Kavur AE, Sudre CH, Baumgartner M, Eisenmann M, Heckmann-Nötzel D, Rädsch T, Acion L, Antonelli M, Arbel T, Bakas S, Benis A, Blaschko MB, Cardoso MJ, Cheplygina V, Cimini BA, Collins GS, Farahani K, Ferrer L, Galdran A, van Ginneken B, Haase R, Hashimoto DA, Hoffman MM, Huisman M, Jannin P, Kahn CE, Kainmueller D, Kainz B, Karargyris A, Karthikesalingam A, Kofler F, Kopp-Schneider A, Kreshuk A, Kurc T, Landman BA, Litjens G, Madani A, Maier-Hein K, Martel AL, Mattson P, Meijering E, Menze B, Moons KGM, Müller H, Nichyporuk B, Nickel F, Petersen J, Rajpoot N, Rieke N, Saez-Rodriguez J, Sánchez CI, Shetty S, van Smeden M, Summers RM, Taha AA, Tiulpin A, Tsaftaris SA, Van Calster B, Varoquaux G, Jäger PF. Maier-Hein L, et al. Nat Methods. 2024 Feb;21(2):195-212. doi: 10.1038/s41592-023-02151-z. Epub 2024 Feb 12. Nat Methods. 2024. PMID: 38347141 Free PMC article. Review.
Concurrent RB1 Loss and BRCA Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma.
Saner FAM, Takahashi K, Budden T, Pandey A, Ariyaratne D, Zwimpfer TA, Meagher NS, Fereday S, Twomey L, Pishas KI, Hoang T, Bolithon A, Traficante N; Australian Ovarian Cancer Study Group; Alsop K, Christie EL, Kang EY, Nelson GS, Ghatage P, Lee CH, Riggan MJ, Alsop J, Beckmann MW, Boros J, Brand AH, Brooks-Wilson A, Carney ME, Coulson P, Courtney-Brooks M, Cushing-Haugen KL, Cybulski C, El-Bahrawy MA, Elishaev E, Erber R, Gayther SA, Gentry-Maharaj A, Gilks CB, Harnett PR, Harris HR, Hartmann A, Hein A, Hendley J, Hernandez BY, Jakubowska A, Jimenez-Linan M, Jones ME, Kaufmann SH, Kennedy CJ, Kluz T, Koziak JM, Kristjansdottir B, Le ND, Lener M, Lester J, Lubiński J, Mateoiu C, Orsulic S, Ruebner M, Schoemaker MJ, Shah M, Sharma R, Sherman ME, Shvetsov YB, Soong TR, Steed H, Sukumvanich P, Talhouk A, Taylor SE, Vierkant RA, Wang C, Widschwendter M, Wilkens LR, Winham SJ, Anglesio MS, Berchuck A, Brenton JD, Campbell I, Cook LS, Doherty JA, Fasching PA, Fortner RT, Goodman MT, Gronwald J, Huntsman DG, Karlan BY, Kelemen LE, Menon U, Modugno F, Pharoah PDP, Schildkraut JM, Sundfeldt K, Swerdlow AJ, Goode EL, DeFazio A, Köbel M, Ramus SJ, Bowtell DDL, Garsed DW. Saner FAM, et al. Clin Cancer Res. 2024 Aug 15;30(16):3481-3498. doi: 10.1158/1078-0432.CCR-23-3552. Clin Cancer Res. 2024. PMID: 38837893 Free PMC article.
HLA-G and HLA-F protein isoform expression in breast cancer patients receiving neoadjuvant treatment.
Wuerfel FM, Huebner H, Häberle L, Gass P, Hein A, Jud SM, Hack CC, Wunderle M, Schulz-Wendtland R, Erber R, Hartmann A, Ekici AB, Beckmann MW, Fasching PA, Ruebner M. Wuerfel FM, et al. Sci Rep. 2020 Sep 25;10(1):15750. doi: 10.1038/s41598-020-72837-3. Sci Rep. 2020. PMID: 32978482 Free PMC article.
The immunosuppressive human leukocyte antigens HLA-G and HLA-F are expressed on trophoblast and malignant cells. Four membrane-bound and three soluble HLA-G protein isoforms have been described, which have different immunosuppressive potentials. HLA-F has three tran …
The immunosuppressive human leukocyte antigens HLA-G and HLA-F are expressed on trophoblast and malignant cells. Four membrane-bound …
190 results